埃尔特罗姆博巴格与免疫抑制疗法结合用于儿科重症无形成性贫血
Bixi Yang1, Lingling Fu1, Hongmin Li1
1Department of Hematology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
将eltrombopag添加到免疫抑制疗法 (IST) 中,可以加速儿科严重无性贫血 (SAA) 患者的血液反应. 虽然它是安全的,但它并没有改善长期结果或生存率.
科学领域:
- 血液学 血液学 血液学
- 儿科瘤学 儿科瘤学
- 免疫抑制是一种免疫抑制.
背景情况:
- 严重的无形性贫血 (SAA) 是由于免疫媒介的破坏而产生的.
- 标准免疫抑制疗法 (IST) 是有效的,但需要加强.
研究的目的:
- 评估在小儿SAA患者中将ELTROMBOPAG添加到IST的疗效和安全性.
- 为了解决关于TPO-RA结合IST在儿科SAA中缺乏临床数据的问题.
主要方法:
- 对接受IST的115名儿科SAA患者的回顾性分析.
- 历史对照研究比较eltrombopag + IST与单独的IST.
主要成果:
- 埃尔特罗姆波巴格组在3个月和6个月后显示出更高的完全响应率 (CRR).
- 在整体反应率 (ORR),整体存活率 (OS) 或无事件存活率 (EFS) 中没有显著差异.
- 埃尔特罗姆波巴格 (Eltrombopag) 证明了可靠的安全性,而不会影响长期预后.
结论:
- 在IST中添加Eltrombopag加快了小儿SAA的血液反应.
- 埃尔特罗姆波帕格是安全的,但不会影响长期结果或预后.
更多相关视频
11:55Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
Published on: March 14, 2011
03:40Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis
Published on: December 8, 2023
相关概念视频
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Tissue Transplantation
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Immunodeficiency Diseases
There are three main causes of immunodeficiency...
